Oklahoma is fertile ground for bioscience growth, talent and premier facilities:

• The Oklahoma Center for the Advancement of Science and Technology (OCAST) has funded 2,525 projects at more than $270 million, attracting $5.8 billion in private sector and federal dollars for a return on investment of 21:1
• The University of Oklahoma Health Sciences Center is dedicated to both basic and translational research, with patient-centered care and research ongoing at the Stephenson Cancer Center, the Harold Hamm Diabetes Center and the Dean McGee Eye Institute
• The 23-acre, $100 million University Research Park, part of the Oklahoma Health Center complex, is home to 38 science-based companies
• The Samuel Roberts Noble Foundation is the largest private foundation in the country conducting plant science and agriculture research
• Oklahoma State University is a leader in agriculture and animal science research
• i2E, Inc. invested more than $1.9 million in five Oklahoma bioscience companies in 2015 and $14.6 million over the past 16 years

Oklahoma bioscience impact:

• The biosciences sector includes hospitals, non-hospital bioscience firms and bioscience academic R&D
• The biosciences generate an estimated $227 million in state and local taxes as a result of its direct and indirect employment
• Firms in the bioscience sector have annual revenues of $4.1 billion
• Greater Oklahoma City’s bioscience sector employs 27,800 workers with total employee compensation of $1.5 billion
• The combined direct and indirect impacts associated with the bioscience sector contribute $6.7 billion in total economic activity to the region, and support 51,000 jobs earning $2.2 billion in wages

Bioscience in Oklahoma truly is driving innovation that is improving lives and creating jobs! Here is a look at some of our emerging bio companies:

• Selexys Pharmaceuticals is focused on development of therapeutics for treatment of inflammation across several disease indications. Their lead human monoclonal antibody program is currently under clinical study in patients with Sickle Cell Disease. Novartis Pharmaceuticals has an exclusive option to acquire the asset upon successful completion of the Phase 2 clinical trial.
• Moleculera Labs is a pioneer in infection-induced autoimmune conditions that disrupt neurologic function. The company currently markets a diagnostic test, the Cunningham Panel, which predicts a patient’s likelihood having Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococci (PANDAS).
• Cytovance Biologics, Inc. is a pharmaceutical contract manufacturer producing biologics, therapeutic proteins and antibodies, and was recently acquired in a $206 million deal. The company employs more than 170, and their products are used globally for clinical trials and research.
• Accele BioPharma, a bioscience business accelerator, has four bio companies under management that focus on infectious disease, diabetes, drug-resistant bacterial infections and hearing loss.
• Immuno Mycologics is listed as one of Inc.’s fastest-growing private companies in the nation. IMMY is a diagnostic manufacturing company that has evolved from a company that filled a need in the infectious disease market to an organization with a global focus on saving lives through innovative products.
• The Arthrokinex comprehensive joint health program can reduce or eliminate joint pain from Osteoarthritis utilizing the healing power in a patient’s own blood. 
• Progentec Diagnostics, Inc. has developed an advanced state-of-the-art Lupus flare diagnostic, which has potential to fundamentally change the current treatment paradigm for Lupus.  The company has partnered with the Oklahoma Medical Research Foundation, a Center of Excellence for Lupus in the US and they are striving to accelerate commercialization of the patented diagnostic technology by early 2018.
• Biolytx is a pharmaceutical technology company developing a novel antibiotic peptide for potential use in wound healing and treatment of serious hospital-acquired infections, including those resistant to current antibiotics.  The technology was developed in the University of Oklahoma Health Sciences Center laboratory of Dr. Anne Pereira and licensed from OU.  

Oklahoma is recognized internationally for the strength of our research institutions:

• Hough Ear Institute
• Laureate Institute of Brain Research
• Oklahoma Medical Research Foundation
• Oklahoma State University
• Samuel Roberts Noble Foundation
• University of Central Oklahoma
• University of Oklahoma Health Sciences Center
  • Dean McGee Eye Institute
  • Stephenson Cancer Center
  • Harold Hamm Diabetes Center
• University of Tulsa

Our research institutions demonstrate excellence in select areas of human, plant and animal science, with strong emphasis in:

• Agricultural productivity
• Autoimmune diseases and immunology
• Biofuels
• Cardiovascular research
• Glycobiology and carbohydrates
• Infectious disease and microbiology
• Natural products for health
• Plant improvement
• Value-added food product
• Vision research

Innovative service providers facilitate the growth of Oklahoma biosciences:

• Accele BioPharma
• ARL/DNA Solutions
• Cytovance Biologics
• Emergent Technologies
• i2E, Inc.
• Lynn Health Sciences Institute
• OKBio Association
• Oklahoma Center for the Advancement of Science and Technology
• Oklahoma Life Science Fund